Peroxisome proliferator-activated receptor · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Peroxisome proliferator-activated receptor shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P37231. Start with cardiovascular disease, then reuse UniProt P37231 as the stable protein anchor across project notes and exports.
Start with cardiovascular disease, then reuse UniProt P37231 as the stable protein anchor across project notes and exports.
Peroxisome proliferator-activated receptor shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with cardiovascular disease because it currently carries approved-linked support. Linked drugs include BEZAFIBRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyPeroxisome proliferator-activated receptor gamma
Review this target as Peroxisome proliferator-activated receptor, mapped to UniProt P37231. ChEMBL maps the protein component as Peroxisome proliferator-activated receptor gamma. Sequence length is 505 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Peroxisome proliferator-activated receptor as ChEMBL target CHEMBL3559683, mapped to UniProt P37231. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Peroxisome proliferator-activated receptor is the right protein anchor across sources, using UniProt P37231 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why cardiovascular disease is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Peroxisome proliferator-activated receptor |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P37231 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Peroxisome proliferator-activated receptor gamma |
| UniProt Accession | P37231 |
| Component Type | Protein |
| Sequence Length | 505 aa |
Peroxisome proliferator-activated receptor gamma
Review this target as Peroxisome proliferator-activated receptor, mapped to UniProt P37231. ChEMBL maps the protein component as Peroxisome proliferator-activated receptor gamma. Sequence length is 505 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Peroxisome proliferator-activated receptor shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block.
Start review with cardiovascular disease because it currently carries approved-linked support. Linked drugs include BEZAFIBRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL458899 | 6.52 | EC50 | 300.0 | Preclinical |
| CHEMBL264374 | 5.98 | EC50 | 1040.0 | Clinical |
| CHEMBL516827 | 5.92 | EC50 | 1200.0 | Preclinical |
| CHEMBL121 | 5.8 | EC50 | 1600.0 | Approved |
| CHEMBL2159607 | 5.28 | EC50 | 5200.0 | Preclinical |
| CHEMBL3353021 | 5.19 | EC50 | 6400.0 | Preclinical |
| CHEMBL2159605 | 5.16 | EC50 | 7000.0 | Preclinical |
| CHEMBL3353020 | 5.09 | EC50 | 8200.0 | Preclinical |
| CHEMBL465800 | 5.0 | EC50 | 9900.0 | Preclinical |
| CHEMBL2159606 | 4.98 | EC50 | 10400.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 23 | 15 | 5.2 |
| protein format | 6 | 0 | — |
| assay format | 4 | 0 | — |